SCHEMBL20600796

SCHEMBL20600796

Cn1cnc2ccc(-c3c(-c4ccc(F)cc4)nc(N)c4nc(CO)cn34)cc21

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADORA2A P29274 8/20 0.46
▸ ADORA1 P30542 7/20 0.46
▸ ADORA2B P29275 4/20 0.46
▸ DYRK1A Q13627 5/20 0.43
▸ MAPK14 Q16539 1/20 0.42
▸ CSNK1D P48730 4/20 0.38
▸ ERBB2 P04626 3/20 0.38
▸ FGFR1 P11362 3/20 0.38
▸ MAPK8 P45983 3/20 0.38
▸ MAPK9 P45984 3/20 0.38
▸ LIMK1 P53667 3/20 0.38
▸ PRKD2 Q9BZL6 3/20 0.38
▸ PIM1 P11309 2/20 0.38
▸ FLT4 P35916 2/20 0.38
▸ PRKD3 O94806 2/20 0.38
▸ MAP4K4 O95819 2/20 0.38
▸ MAP4K2 Q12851 2/20 0.38
▸ CAMK2B Q13554 2/20 0.38
▸ ERBB4 Q15303 2/20 0.38
▸ TAOK1 Q7L7X3 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20600539 0.89 ADORA2A (0.45) ADORA2AADORA1ADORA2BDYRK1AMAPK14
SCHEMBL22125673 0.86 ADORA2A (0.45) ADORA2AADORA1ADORA2BDYRK1AMAPK14
SCHEMBL20600751 0.85 ADORA2A (0.44) ADORA2AADORA1ADORA2BDYRK1AMAPK14
SCHEMBL20600831 0.85 ADORA2A (0.46) ADORA2AADORA1ADORA2BDYRK1AMAPK14
SCHEMBL20600644 0.84 ADORA2A (0.46) ADORA2AADORA1ADORA2BDYRK1AMAPK14
SCHEMBL20624720 0.84 MAPK14 (0.44) ADORA2AADORA1ADORA2BDYRK1AMAPK14
SCHEMBL20624719 0.83 ADORA2A (0.49) ADORA2AADORA1ADORA2BDYRK1AMAPK14
Lithium Ion SCHEMBL31360793 0.83 ADORA2A (0.43) ADORA2AADORA1ADORA2BDYRK1AMAPK14
SCHEMBL22125595 0.83 ADORA2A (0.45) ADORA2AADORA1ADORA2BDYRK1AMAPK14
SCHEMBL20600440 0.83 ADORA2A (0.48) ADORA2AADORA1ADORA2BDYRK1AMAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200369665-A1 IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR Ryvu Therapeutics S.A. (PL) 2020-11-26 — — US claimed
US-20200369665-A1 IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR Ryvu Therapeutics S.A. (PL) 2020-11-26 — — US disclosed
US-20200369665-A1 IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR Ryvu Therapeutics S.A. (PL) 2020-11-26 — — US disclosed
WO-2020128036-A1 MODULATORS OF THE ADENOSINE A2A RECEPTOR Ryvu Therapeutics S.A. (PL) 2020-06-25 — — WO disclosed
EP-3645536-A1 IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR Ryvu Therapeutics S.A. (PL) 2020-05-06 — — EP disclosed
WO-2019002606-A1 IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR SELVITA S.A. (PL) 2019-01-03 — — WO disclosed
WO-2019002606-A1 IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR SELVITA S.A. (PL) 2019-01-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200369665-A1 IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR ADORA2A, ADORA1, ADORA3 ADORA2A 1/4885ADORA1 2/4885ADORA2B 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback